Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

AbbVie (NYSE:ABBV)

• Dividend Yield: 3.30%
• Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $294 to $298 on May 14, 2026. This analyst has an accuracy rate of 77%
• Guggenheim analyst Vamil Divan maintained a Buy rating with a price target of $249 on May 1, 2026. This analyst has an accuracy rate of 78%.
• Recent News: On April 29, AbbVie reported better-than-expected first-quarter financial results.
• Benzinga Pro’s real-time newsfeed alerted to latest ABBV news.

GSK plc (NYSE:GSK)

• Dividend Yield: 3.58%
• Barclays analyst James Gordondowngraded the stock from Equal-Weight to Underweight on Jan. 6, 2026. This analyst has an accuracy rate of 63%.
• Jefferies analyst Michael Leuchten upgraded the stock from Hold to Buy on Oct. 27, 2025. This analyst has an accuracy rate of 63%
• Recent News: On May 18, GSK Arexvy RSV vaccine gained Japan approval for adults 18-49 at increased risk as immunocompromised added to label.
• Benzinga Pro's real-time newsfeed alerted to latest GSK news

Bristol-Myers Squibb Co (NYSE:BMY)

• Dividend Yield: 4.40%
• B of A Securities analyst Tim Anderson maintained a Buy rating and cut the price target from $68 to $67 on April 9, 2026. This analyst has an accuracy rate of 52%
• Guggenheim analyst Seamus Fernandez maintained a Buy rating with a price target of $72 on April 8, 2026. This analyst has an accuracy rate of 75%.
• Recent News: On May 12, Bristol-Myers Squibb announced a partnership with Hengrui Pharma to develop a portfolio of 13 early-stage programs spanning oncology, hematology and immunology.
• Benzinga Pro’s real-time newsfeed alerted to latest BMY news

Photo via Shutterstock